Numab is thrilled to announce that Johnson & Johnson has entered into a definitive agreement to acquire Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab that holds the rights to NM26. NM26 is an investigational first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis, discovered and engineered through Numab’s proprietary MATCH™ technology platform. Johnson & Johnson will pay a purchase price of $1.25 billion and will gain the full rights to develop, manufacture and commercialize NM26 globally for atopic dermatitis and follow-on indications. This acquisition further validates our discovery and engineering platform and its potential to bring novel multi-specific antibodies to underserved patient populations. To learn more, please read our press release: https://lnkd.in/daWRtKVR
Well done David Urech and team at Numab Therapeutics AG. Tremendous validation.
Herzlichen Glückwunsch allen Beteiligten und von mir ganz besonders an David Urech und Roland Helfenstein. Grossartige Story liebe Kollegen.
Gratuliere zu diesem Top Deal, sehr beeindruckend! Ganz herzliche Grüsse ins Züribiet an Dave, Oli, Peter und Tea, die ich noch aus der ESBATech Zeit her kenne :-)
Congratulations and well done!
Congratulations and well done!
Well done!
Congratulations to the Numab team; this is fantastic news!
Hey, that's what I call good news... Congrats Peter @Team ! Well diserved... 💪
Chief Executive Officer, iCell Gene Therapeutics
5moGreat news for my many friends at Numab!!! And their investors!!! Have been admiring your visionary science and approach for more than decade! Peter Lichtlen Oliver Middendorp Taryn Losch-Beridon James Egan